Bibliometric Analysis on GABA-A Receptors Research Based on CiteSpace and VOSviewer.
CiteSpace
GABA
GABA-A receptor
VOSviewer
trends
visual analysis
Journal
Journal of pain research
ISSN: 1178-7090
Titre abrégé: J Pain Res
Pays: New Zealand
ID NLM: 101540514
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
03
2023
accepted:
11
05
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
epublish
Résumé
GABA-A receptors are the primary mediators of brain inhibitory neurotransmission. In the past years, many studies focused on this channel to decipher the pathogenesis of related diseases but lacked bibliometric analysis research. This study aims to explore the research status and identify the research trends of GABA-A receptor channels. Publications related to GABA-A receptor channels were retrieved from the Web of Science Core Collection from 2012 to 2022. After screening, the VOSviewer 1.6.18 and Citespace 5.8 R3 were used for bibliometric analysis from journals, countries, institutions, authors, co-cited references and keywords. We included 12,124 publications in the field of GABA-A receptor channels for analysis. The data shows that although there was a slight decrease in annual publications from 2012 to 2021, it remained at a relatively high level. Most publications were in the domain of neuroscience. Additionally, the United States was the most prolific country, followed by China. Univ Toronto was the most productive institution, and James M Cook led essential findings in this field. Furthermore, brain activation, GABAAR subunits expression, modulation mechanism in pain and anxiety behaviors and GABA and dopamine were paid attention to by researchers. And top research frontiers were molecular docking, autoimmune encephalitic series, obesity, sex difference, diagnosis and management, EEG and KCC2. Taken together, academic attention on GABA-A receptor channels was never neglected since 2012. Our analysis identified key information, such as core countries, institutions and authors in this field. Molecular docking, autoimmune encephalitic series, obesity, sex difference, diagnosis and management, EEG and KCC2 will be the future research direction.
Sections du résumé
Background
UNASSIGNED
GABA-A receptors are the primary mediators of brain inhibitory neurotransmission. In the past years, many studies focused on this channel to decipher the pathogenesis of related diseases but lacked bibliometric analysis research. This study aims to explore the research status and identify the research trends of GABA-A receptor channels.
Methods
UNASSIGNED
Publications related to GABA-A receptor channels were retrieved from the Web of Science Core Collection from 2012 to 2022. After screening, the VOSviewer 1.6.18 and Citespace 5.8 R3 were used for bibliometric analysis from journals, countries, institutions, authors, co-cited references and keywords.
Results
UNASSIGNED
We included 12,124 publications in the field of GABA-A receptor channels for analysis. The data shows that although there was a slight decrease in annual publications from 2012 to 2021, it remained at a relatively high level. Most publications were in the domain of neuroscience. Additionally, the United States was the most prolific country, followed by China. Univ Toronto was the most productive institution, and James M Cook led essential findings in this field. Furthermore, brain activation, GABAAR subunits expression, modulation mechanism in pain and anxiety behaviors and GABA and dopamine were paid attention to by researchers. And top research frontiers were molecular docking, autoimmune encephalitic series, obesity, sex difference, diagnosis and management, EEG and KCC2.
Conclusion
UNASSIGNED
Taken together, academic attention on GABA-A receptor channels was never neglected since 2012. Our analysis identified key information, such as core countries, institutions and authors in this field. Molecular docking, autoimmune encephalitic series, obesity, sex difference, diagnosis and management, EEG and KCC2 will be the future research direction.
Identifiants
pubmed: 37361426
doi: 10.2147/JPR.S409380
pii: 409380
pmc: PMC10289248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2101-2114Informations de copyright
© 2023 Yu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Pharmacol Ther. 2022 Jun;234:108035
pubmed: 34793859
JAMA Neurol. 2017 Sep 1;74(9):1130-1139
pubmed: 28655027
Neuropsychopharmacology. 2019 Jan;44(1):111-128
pubmed: 30061743
Neuropharmacology. 2012 Jan;62(1):42-53
pubmed: 21889518
Ear Nose Throat J. 2021 Jul 31;:1455613211037641
pubmed: 34337975
Comput Biol Chem. 2021 Feb;90:107402
pubmed: 33338839
Pharmacol Ther. 2006 Jan;109(1-2):12-32
pubmed: 15996746
Stroke. 2010 May;41(5):1018-26
pubmed: 20360540
Restor Neurol Neurosci. 2019;37(4):315-331
pubmed: 31227671
J Integr Neurosci. 2021 Mar 30;20(1):173-184
pubmed: 33834705
Nature. 2019 Jan;565(7740):454-459
pubmed: 30602790
AMIA Annu Symp Proc. 2005;:724-8
pubmed: 16779135
Nature. 2014 Aug 21;512(7514):270-5
pubmed: 24909990
Pharmacol Res. 2021 Jul;169:105645
pubmed: 33957268
Nat Rev Drug Discov. 2011 Jul 29;10(9):685-97
pubmed: 21799515
Nat Neurosci. 1999 Sep;2(9):833-9
pubmed: 10461223
Nat Commun. 2015 Apr 20;6:6872
pubmed: 25891999
AJNR Am J Neuroradiol. 2017 Jun;38(6):1070-1078
pubmed: 28183838
Expert Opin Investig Drugs. 2010 Oct;19(10):1217-33
pubmed: 20812877
Mol Imaging Biol. 2020 Apr;22(2):223-244
pubmed: 31168682
J Neurochem. 2006 Aug;98(3):641-53
pubmed: 16787421
Curr Opin Pharmacol. 2021 Aug;59:3-10
pubmed: 34020139
Neuroreport. 2017 Dec 13;28(18):1255-1260
pubmed: 29099440
Biol Open. 2020 Apr 13;9(4):
pubmed: 32205311
J Recept Signal Transduct Res. 2006;26(5-6):731-40
pubmed: 17118808
Int J Environ Res Public Health. 2021 Oct 15;18(20):
pubmed: 34682602
J Neurosci. 2016 Dec 7;36(49):12312-12320
pubmed: 27927951
Neuron. 2012 Jan 12;73(1):23-34
pubmed: 22243744
Neuron. 2019 Jun 5;102(5):1088
pubmed: 31170393
Int J Mol Sci. 2021 Sep 06;22(17):
pubmed: 34502550
Curr Pharm Des. 2015;21(34):4943-59
pubmed: 26365137
Ann Transl Med. 2020 Jul;8(13):816
pubmed: 32793661
Iran J Public Health. 2019 Apr;48(4):621-631
pubmed: 31110972
Neuroimage. 2020 Oct 15;220:117079
pubmed: 32585345
Neuropharmacology. 2018 Jul 1;136(Pt A):10-22
pubmed: 29407219
J Orthop Surg Res. 2021 Jul 17;16(1):460
pubmed: 34273999
Lancet Neurol. 2010 Aug;9(8):776-85
pubmed: 20580615
Psychoneuroendocrinology. 2017 Nov;85:78-87
pubmed: 28837909
Cell. 2019 Jan 10;176(1-2):1
pubmed: 30633900
Periodontol 2000. 2020 Feb;82(1):286-297
pubmed: 31850637
Neuroscientist. 2002 Dec;8(6):562-73
pubmed: 12467378
Expert Opin Biol Ther. 2014 Sep;14(9):1295-317
pubmed: 25077605
Neuroreport. 2019 Aug 7;30(11):753-759
pubmed: 31261237
Nat Neurosci. 2021 Apr;24(4):529-541
pubmed: 33589833
PLoS One. 2019 Oct 31;14(10):e0223994
pubmed: 31671124
World J Biol Psychiatry. 2018;19(sup1):S36-S45
pubmed: 30204559
Curr Drug Targets. 2019;20(5):501-521
pubmed: 30360733
Neurology. 2013 Oct 22;81(17):1500-6
pubmed: 24068784
Membranes (Basel). 2022 Apr 19;12(5):
pubmed: 35629767
Neuropharmacology. 2021 Sep 1;195:108675
pubmed: 34153311
Int J Mol Sci. 2021 Feb 01;22(3):
pubmed: 33535681
Psychopharmacology (Berl). 1995 Sep;121(1):38-56
pubmed: 8539340
Sci Rep. 2016 Sep 12;6:33095
pubmed: 27615800
Neuropsychopharmacology. 2011 Oct;36(11):2222-32
pubmed: 21750581
Mol Psychiatry. 2021 Jul;26(7):2837-2853
pubmed: 33767348
Toxicol Lett. 2001 Jul 6;122(3):215-22
pubmed: 11489356
Aging (Albany NY). 2021 Aug 4;13(15):19529-19541
pubmed: 34349039
Nature. 2011 Jun 2;474(7349):54-60
pubmed: 21572436
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3576-81
pubmed: 25730879
J Child Neurol. 2003 Jan;18(1):39-48; discussion 49
pubmed: 12661937
Trends Mol Med. 2011 Aug;17(8):452-62
pubmed: 21514225
Neurogenetics. 2006 Jul;7(3):167-74
pubmed: 16770606
Biomolecules. 2023 Jan 18;13(2):
pubmed: 36830567
J Neurol. 2010 Apr;257(4):509-17
pubmed: 20035430